TT-173

Thrombotargets Europe S.L · Phase 2 active Biologic

At a glance

Generic name	TT-173
Also known as	topical hemostatic agent
Sponsor	Thrombotargets Europe S.L
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT) (PHASE2, PHASE3)
Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting (PHASE2)
Safety, Tolerability and Efficacy Study of TT-173 in Healthy Volunteers After Tooth Extraction (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TT-173 CI brief — competitive landscape report
TT-173 updates RSS · CI watch RSS
Thrombotargets Europe S.L portfolio CI